Leukopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Leucopenia occurred more often in the CYC group compared to the TwHF group (P = 0.034).
|
31713733 |
2020 |
Granulomatosis with polyangiitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Although the use of glucocorticoids with CYC is the most common drug combination, no differences in the outcome of the pituitary function and GPA disease course are seen with other immunosuppressants.
|
31446541 |
2020 |
Angina, Unstable
|
0.010 |
Biomarker
|
disease |
BEFREE |
Eighty-four consecutive type 2 diabetic patients with unstable angina (UA) were included from January 2018 to June 2018 to calculate calcification scores using computerized tomographic angiography (CTA), and the patients were divided into 2 groups: high calcification score group (HCS group) and low calcification score group (LCS group).
|
31452690 |
2019 |
Behcet Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
CYC remains an important treatment option for Behçet's syndrome (BS) patients with life-threatening manifestations.
|
31840168 |
2019 |
Bloom Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We investigated short and long term adverse events associated with CYC use in BS patients.
|
31840168 |
2019 |
Chediak-Higashi Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We used two human CHS cell lines SW1353 and HCS-2/8 to analyze the expression profiles of ADAM8 in CHS cells compared with the normal chondrocytes.
|
31305294 |
2019 |
Lupus Nephritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Treatment with a combined immunosuppressive agent is superior to routine CYC only therapy in lupus nephritis.
|
30488367 |
2019 |
Retinitis Pigmentosa
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations</b>: CYCS: cytochrome c; bRHO<sup>P23H</sup>: bovine RHO<sup>P23H</sup>; Cas9: CRISPR associated protein 9; dpf: days post-fertilization; eGFP: enhanced green fluorescent protein; GNAT1: guanine nucleotide-binding protein G(t) subunit alpha-1 aka rod alpha-transducin; HSPA1A/hsp70: heat shock protein of 70 kilodaltons; LAMP1: lysosomal-associated membrane protein 1; LC3: microtubule-associated protein 1A/1B light chain 3; mRFP: monomeric red fluorescent protein; RHO: rhodopsin; RP: retinitis pigmentosa; RPE65: retinal pigment epithelium-specific 65 kDa protein: sfGFP: superfolding GFP; sgRNA: single guide RNA; WGA: wheat germ agglutinin; <i>RHO<sub>p</sub></i>: the <i>Xenopus laevis RHO.2.L</i> promoter.
|
30975014 |
2019 |
Vasculitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, adverse events may occur with CYC and this has led to increased use of biologic agents in other vasculitides.
|
31840168 |
2019 |
Frontotemporal dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations:</b> 4HPR: 4-hydroxy(phenyl)retinamide; AKT: AKT1 serine/threonine kinase 1; ALS: amyotrophic lateral sclerosis; ATG: autophagy related; AVs: autophagic vesicle; C9orf72: chromosome 9 open reading frame 72; CASP3: caspase 3; CHAT: choline O-acetyltransferase; CYCS: cytochrome c, somatic; DIV: day in vitro; FTD: frontotemporal dementia; FUS: FUS RNA binding protein; GFP: green fluorescent protein; hiPSCs: human induced pluripotent stem cells; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MNs: motoneurons; mRFP: monomeric red fluorescent protein; MTOR: mechanistic target of rapamycin kinase; NFE2L2/NRF2: nuclear factor, erythroid 2 like 2; RARA: retinoic acid receptor alpha; SLC18A3/VACHT: solute carrier family 18 (vesicular acetylcholine transporter), member 3; SQSTM1/p62: sequestosome 1; TBK1: TANK binding kinase 1; TEM: transmission electron microscopy.
|
30939964 |
2019 |
Diffuse Scleroderma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We concluded that i.v.CYC pulse therapy should be considered as an effective treatment option for skin thickening in dcSSc patients, because 43% of this group of patients were found to have a clinically relevant response.
|
31628802 |
2019 |
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Then, by silencing or overexpressing ADAM8, the effects on cell migration and invasion in SW1353 and HCS-2/8, and the downstream signal transduction pathways were evaluated.
|
31305294 |
2019 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overall outcomes were comparable to those of two matched cohorts (n = 172) from previous European Vasculitis Society (EUVAS) trials, but with lower total exposure to CYC and GCs (P < 0.001) and reduced rates of severe infections (P = 0.02) compared with the RITUXVAS (rituximab versus cyclophosphamide in AAV) trial.
|
30239910 |
2019 |
Head and Neck Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In this chapter, we describe the HCS assay methods to measure IL-6-induced STAT3 signaling pathway activation in head and neck tumor cell lines as revealed by the expression and subcellular distribution of pSTAT3-Y705, pSTAT3-S727, and U-STAT3.
|
29082496 |
2018 |
Skin Manifestations
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The aim of the study was to compare the efficacy and safety of RTX compared with CYC in retarding the progression of interstitial lung disease and skin manifestations of primary SSc.
|
30053212 |
2018 |
Arterial aneurysm
|
0.010 |
Biomarker
|
disease |
BEFREE |
CYC and high dose glucocorticoids decreased mortality in pulmonary arterial aneurysms and postoperative complications in peripheral artery aneurysms.
|
30107448 |
2018 |
Progressive Neoplastic Disease
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Progressive disease that was unresponsive to augmented immunosuppression with CYC was seen in five patients.
|
29562252 |
2018 |
Idiopathic Inflammatory Myopathies
|
0.010 |
Biomarker
|
disease |
BEFREE |
We report the first cohort study of PO CYC use in IIM patients with severe, treatment refractory disease.
|
29971584 |
2018 |
Progressive cGVHD
|
0.010 |
Biomarker
|
disease |
BEFREE |
Progressive disease that was unresponsive to augmented immunosuppression with CYC was seen in five patients.
|
29562252 |
2018 |
Immunosuppression
|
0.010 |
Biomarker
|
disease |
BEFREE |
Progressive disease that was unresponsive to augmented immunosuppression with CYC was seen in five patients.
|
29562252 |
2018 |
Encephalitis, St. Louis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two subcohorts of treated SLE patients were defined on the basis of treatment with antimalarials (n = 1942) and other immunosuppressants (AZA, CYC, ciclosporin, MTX, MMF or rituximab; n = 2175).
|
28039412 |
2017 |
Secondary malignant neoplasm of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this review, we will highlight the macrophage functions in the skeleton, in the maintenance of the HCS niches, and their importance in bone metastasis.
|
28247013 |
2017 |
Cervical intraepithelial neoplasia grade 2
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, the transcription of PCBP2, MCM5, hnRNPA1, TYPH, and CYC was also significantly increased in cervical intraepithelial neoplasia II-III compared to normal cervix.
|
28443473 |
2017 |
Cystinuria
|
0.010 |
Biomarker
|
disease |
BEFREE |
The affected siblings display a recognizable phenotype which is similar to atypical HCS with regard to growth failure and neuro-muscular features, but is characterized by lack of cystinuria.
|
23794250 |
2013 |
Failure to Thrive
|
0.010 |
Biomarker
|
disease |
BEFREE |
The affected siblings display a recognizable phenotype which is similar to atypical HCS with regard to growth failure and neuro-muscular features, but is characterized by lack of cystinuria.
|
23794250 |
2013 |